.png){kind=icon}
返回
Workforce Considerations When Building a Precision Medicine Program
.png){kind=icon}
OA
AI
DOI：10.3390/jpm12111929.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
This paper describes one healthcare system's approach to strategically deploying genetic specialists and pharmacists to support the implementation of a precision medicine program. In 2013, Sanford Health initiated the development of a healthcare system-wide precision medicine program. Here, we report the necessary staffing including the genetic counselors, genetic counseling assistants, pharmacists, and geneticists. We examined the administrative and electronic medical records data to summarize genetic referrals over time as well as the uptake and results of an enterprise-wide genetic screening test. Between 2013 and 2020, the number of genetic specialists employed at Sanford Health increased by 190%, from 10.1 full-time equivalents (FTEs) to 29.3 FTEs. Over the same period, referrals from multiple provider types to genetic services increased by 423%, from 1438 referrals to 7517 referrals. Between 2018 and 2020, 11,771 patients received a genetic screening, with 4% identified with potential monogenic medically actionable predisposition (MAP) findings and 95% identified with at least one informative pharmacogenetic result. Of the MAP-positive patients, 85% had completed a session with a genetics provider. A strategic workforce staffing and deployment allowed Sanford Health to manage a new genetic screening program, which prompted a large increase in genetic referrals. This approach can be used as a template for other healthcare systems interested in the development of a precision medicine program.
Keyword:
workforce
genetic counseling
genetic testing
pharmacogenetics
precision medicine
humans
genetic predisposition to dis-ease
delivery of health care
mass screening
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
3
论文数:
7.5K
被引数:
1.3W
机构
引用论文
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.png)
GENETICS IN MEDICINEOAAI
GENETICS IN MEDICINEIF6.2
OAAI分享收藏Cost‐effectiveness of the oral adsorbent AST‐120 versus placebo for chronic kidney diseaseNephrology
NephrologyIF0
PREAI
分享收藏Primary-care physicians' access to genetic specialists: an impediment to the routine use of genomic medicine?GENETICS IN MEDICINEOAAI
GENETICS IN MEDICINEIF6.2
OAAI分享收藏Primary care providers' responses to unsolicited Lynch syndrome secondary findings of varying clinical significanceGENETICS IN MEDICINEOAAI
GENETICS IN MEDICINEIF6.2
OAAI分享收藏
查看更多内容